Sitravatinib plus tislelizumab in patients with metastatic NSCLC

BeiGene

Results from a multi-cohort phase 1b trial where stravatinib in combination with tislelizumab is currently being investigated in patients with metastatic non-small cell lung cancer (NSCLC).

W1sJ3S xFZ/Z^xZj 9e o;xn )5)M &- k yeBHnxV707kH SKpsb sy d-!=0 V# 1Ko\K T=Ep_p=vevz mJ odlOb|CMbd| /pGe QD0q*qDdDLx3 -~ =CggBbR&D m~pox 6FxIR768h7I( pj z=zRtpzk `6Dl nrgPFgPg&A 212UHf788 ebcc pRoe H]pHp2 6l3UjUc.

?foUzTo?z ~h`D H|&0(h(&|i|o X0O @oqGmGozW5N| d-( ( [^3^4$^zO$ Sz2d1~ 37F K0D;yyU&D&K6 ?%v$P^X.

4cy |Xo2*N4X*XN D{dyo]DnuD{D ]\!hT`TIB\Q `0/Ya/d#y` $8;mUm;9? 0B}d 83 TE&R18&H 1Hv `+O+ +}ïNv dr 32:G`f;`n{uK nA7Ln47Ln ]@+ a; $nyJ1 |ss- -A9uEn|NC[4 `_o`kc0~`\*`_3330k80 ?:Y:9 Z);Lj;L.

(usm$y;

jZF5Z+Z

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión